Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Dearden

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
American Journal of Cancer Research|November 27, 2015
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)Anita Midha, Simon Dearden, Rose McCormack
Journal of Experimental & Clinical Cancer Research : CR|September 5, 2015
Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature reviewJames Sherwood, Simon Dearden, Marianne Ratcliffe, et al.
Journal of Clinical Pathology|November 23, 2012
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesGillian Ellison, Guanshan Zhu, Alexandros Moulis, et al.
Lung Cancer (Amsterdam, Netherlands)|June 5, 2017
EGFR T790M mutation testing within the osimertinib AURA Phase I studySimon Dearden, Helen Brown, Suzanne Jenkins, et al.
Human Molecular Genetics|June 21, 2002
Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201G Malcolm Taylor, Simon Dearden, Paul Ravetto, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2015
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291Kenneth S Thress, Roz Brant, T Hedley Carr, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2013
KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranibJohn C Smith, Laura Brooks, Paulo M Hoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR statusJean-Yves Douillard, Gyula Ostoros, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2017
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of OsimertinibSuzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, et al.
Virchows Archiv : an International Journal of Pathology|January 29, 2013
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumoursRoy Milner, Helen Wombwell, Sonia Eckersley, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
American Journal of Cancer Research|November 27, 2015
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)Anita Midha, Simon Dearden, Rose McCormack
Journal of Experimental & Clinical Cancer Research : CR|September 5, 2015
Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature reviewJames Sherwood, Simon Dearden, Marianne Ratcliffe, et al.
Journal of Clinical Pathology|November 23, 2012
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesGillian Ellison, Guanshan Zhu, Alexandros Moulis, et al.
Lung Cancer (Amsterdam, Netherlands)|June 5, 2017
EGFR T790M mutation testing within the osimertinib AURA Phase I studySimon Dearden, Helen Brown, Suzanne Jenkins, et al.
Human Molecular Genetics|June 21, 2002
Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201G Malcolm Taylor, Simon Dearden, Paul Ravetto, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2015
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291Kenneth S Thress, Roz Brant, T Hedley Carr, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2013
KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranibJohn C Smith, Laura Brooks, Paulo M Hoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR statusJean-Yves Douillard, Gyula Ostoros, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2017
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of OsimertinibSuzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, et al.
Virchows Archiv : an International Journal of Pathology|January 29, 2013
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumoursRoy Milner, Helen Wombwell, Sonia Eckersley, et al.
Pageof 2